JP2012502099A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502099A5 JP2012502099A5 JP2011526911A JP2011526911A JP2012502099A5 JP 2012502099 A5 JP2012502099 A5 JP 2012502099A5 JP 2011526911 A JP2011526911 A JP 2011526911A JP 2011526911 A JP2011526911 A JP 2011526911A JP 2012502099 A5 JP2012502099 A5 JP 2012502099A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- phenyl
- substituted
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 57
- 239000001257 hydrogen Substances 0.000 claims 48
- 229910052739 hydrogen Inorganic materials 0.000 claims 48
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 28
- 125000001475 halogen functional group Chemical group 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- -1 oxazolidinonyl Chemical group 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 125000004076 pyridyl group Chemical group 0.000 claims 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 3
- 239000005977 Ethylene Substances 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000006485 halo alkoxy phenyl group Chemical group 0.000 claims 2
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims 2
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 2
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 1
- XURRMIFBSMXPNQ-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-methyl-5-[2-methyl-5-[(1-pyridin-2-ylcyclopropyl)carbamoyl]phenyl]furo[2,3-b]pyridine-3-carboxamide Chemical compound C1=C2C(C(=O)NC)=C(C=3C=CC(F)=CC=3)OC2=NC=C1C(C(=CC=1)C)=CC=1C(=O)NC1(C=2N=CC=CC=2)CC1 XURRMIFBSMXPNQ-UHFFFAOYSA-N 0.000 claims 1
- KNNMXGXSXRHBOL-UHFFFAOYSA-N 4-fluoro-2-(4-fluorophenyl)-5-[4-methoxy-2-methyl-5-[(1-phenylcyclopropyl)carbamoyl]phenyl]-n-methylpyrazolo[1,5-a]pyridine-3-carboxamide Chemical compound FC=1C2=C(C(=O)NC)C(C=3C=CC(F)=CC=3)=NN2C=CC=1C(C(=CC=1OC)C)=CC=1C(=O)NC1(C=2C=CC=CC=2)CC1 KNNMXGXSXRHBOL-UHFFFAOYSA-N 0.000 claims 1
- OTBSQLPRKDTTTA-UHFFFAOYSA-N 4-fluoro-2-(4-fluorophenyl)-5-[4-methoxy-2-methyl-5-[(1-pyridin-2-ylcyclopropyl)carbamoyl]phenyl]-n-methylpyrazolo[1,5-a]pyridine-3-carboxamide Chemical compound FC=1C2=C(C(=O)NC)C(C=3C=CC(F)=CC=3)=NN2C=CC=1C(C(=CC=1OC)C)=CC=1C(=O)NC1(C=2N=CC=CC=2)CC1 OTBSQLPRKDTTTA-UHFFFAOYSA-N 0.000 claims 1
- GMLCXKWUSURGFL-UHFFFAOYSA-N 4-fluoro-2-(4-fluorophenyl)-5-[4-methoxy-2-methyl-5-[(1-pyrimidin-2-ylcyclopropyl)carbamoyl]phenyl]-n-methylpyrazolo[1,5-a]pyridine-3-carboxamide Chemical compound FC=1C2=C(C(=O)NC)C(C=3C=CC(F)=CC=3)=NN2C=CC=1C(C(=CC=1OC)C)=CC=1C(=O)NC1(C=2N=CC=CN=2)CC1 GMLCXKWUSURGFL-UHFFFAOYSA-N 0.000 claims 1
- JLTBDDSEOIPNLH-UHFFFAOYSA-N 4-fluoro-2-(4-fluorophenyl)-5-[4-methoxy-2-methyl-5-[[1-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropyl]carbamoyl]phenyl]-n-methylpyrazolo[1,5-a]pyridine-3-carboxamide Chemical compound FC=1C2=C(C(=O)NC)C(C=3C=CC(F)=CC=3)=NN2C=CC=1C(C(=CC=1OC)C)=CC=1C(=O)NC1(C=2ON=C(C)N=2)CC1 JLTBDDSEOIPNLH-UHFFFAOYSA-N 0.000 claims 1
- BGASFGUXQMQWQE-UHFFFAOYSA-N 4-fluoro-2-(4-fluorophenyl)-5-[5-[[1-(3-fluorophenyl)cyclopropyl]carbamoyl]-4-methoxy-2-methylphenyl]-n-methylpyrazolo[1,5-a]pyridine-3-carboxamide Chemical compound FC=1C2=C(C(=O)NC)C(C=3C=CC(F)=CC=3)=NN2C=CC=1C(C(=CC=1OC)C)=CC=1C(=O)NC1(C=2C=C(F)C=CC=2)CC1 BGASFGUXQMQWQE-UHFFFAOYSA-N 0.000 claims 1
- CQJSQVPMDYGFCR-UHFFFAOYSA-N 4-fluoro-2-(4-fluorophenyl)-n-methyl-5-[2-methyl-5-[(1-phenylcyclopropyl)carbamoyl]phenyl]pyrazolo[1,5-a]pyridine-3-carboxamide Chemical compound FC=1C2=C(C(=O)NC)C(C=3C=CC(F)=CC=3)=NN2C=CC=1C(C(=CC=1)C)=CC=1C(=O)NC1(C=2C=CC=CC=2)CC1 CQJSQVPMDYGFCR-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- JPCHBOVBIIMZRS-UHFFFAOYSA-N 5-[2-chloro-5-[(1-pyridin-2-ylcyclopropyl)carbamoyl]phenyl]-2-(4-fluorophenyl)-n-methylfuro[2,3-b]pyridine-3-carboxamide Chemical compound C1=C2C(C(=O)NC)=C(C=3C=CC(F)=CC=3)OC2=NC=C1C(C(=CC=1)Cl)=CC=1C(=O)NC1(C=2N=CC=CC=2)CC1 JPCHBOVBIIMZRS-UHFFFAOYSA-N 0.000 claims 1
- ILQPPJXZVMMEMW-UHFFFAOYSA-N 6-[ethyl(methylsulfonyl)amino]-2-(4-fluorophenyl)-n-methyl-5-[3-(2-phenylpropan-2-ylcarbamoyl)phenyl]pyrazolo[1,5-a]pyridine-3-carboxamide Chemical compound CCN(S(C)(=O)=O)C1=CN2N=C(C=3C=CC(F)=CC=3)C(C(=O)NC)=C2C=C1C(C=1)=CC=CC=1C(=O)NC(C)(C)C1=CC=CC=C1 ILQPPJXZVMMEMW-UHFFFAOYSA-N 0.000 claims 1
- QDVYJFBPZGOAIP-UHFFFAOYSA-N 6-[ethyl(methylsulfonyl)amino]-2-(4-fluorophenyl)-n-methyl-5-[3-[(1-pyridin-2-ylcyclopropyl)carbamoyl]phenyl]pyrazolo[1,5-a]pyridine-3-carboxamide Chemical compound CCN(S(C)(=O)=O)C1=CN2N=C(C=3C=CC(F)=CC=3)C(C(=O)NC)=C2C=C1C(C=1)=CC=CC=1C(=O)NC1(C=2N=CC=CC=2)CC1 QDVYJFBPZGOAIP-UHFFFAOYSA-N 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- 229940100601 interleukin-6 Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 229960000888 rimantadine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9600408P | 2008-09-11 | 2008-09-11 | |
| US61/096,004 | 2008-09-11 | ||
| PCT/US2009/055648 WO2010030538A2 (en) | 2008-09-11 | 2009-09-02 | Compounds for the treatment of hepatitis c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012502099A JP2012502099A (ja) | 2012-01-26 |
| JP2012502099A5 true JP2012502099A5 (enExample) | 2012-10-11 |
Family
ID=41203516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011526911A Pending JP2012502099A (ja) | 2008-09-11 | 2009-09-02 | Ｃ型肝炎の治療のための化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8198449B2 (enExample) |
| EP (1) | EP2331502B1 (enExample) |
| JP (1) | JP2012502099A (enExample) |
| KR (1) | KR20110056537A (enExample) |
| CN (2) | CN103864783A (enExample) |
| AR (1) | AR073586A1 (enExample) |
| AU (1) | AU2009291993A1 (enExample) |
| MX (1) | MX2011002471A (enExample) |
| TW (1) | TW201014855A (enExample) |
| WO (1) | WO2010030538A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010311511B2 (en) | 2009-10-30 | 2014-07-17 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors |
| CN106866667B (zh) * | 2009-11-05 | 2019-11-15 | 圣母大学 | 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法 |
| FR2953520B1 (fr) * | 2009-12-04 | 2011-11-25 | Sanofi Aventis | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
| US8324212B2 (en) | 2010-02-25 | 2012-12-04 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| CN102906089A (zh) * | 2010-03-10 | 2013-01-30 | 百时美施贵宝公司 | 用于治疗丙型肝炎的化合物 |
| US8354410B2 (en) | 2010-03-11 | 2013-01-15 | Bristol-Meyers Squibb Company | Compounds for the treatment of hepatitis C |
| AR082453A1 (es) * | 2010-04-21 | 2012-12-12 | Novartis Ag | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
| US8445497B2 (en) | 2010-06-30 | 2013-05-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| EP2630128A1 (en) * | 2010-10-20 | 2013-08-28 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| JP5731004B2 (ja) | 2010-10-26 | 2015-06-10 | プレシディオ ファーマシューティカルズ インコーポレイテッド | Ｃ型肝炎ウイルスの阻害剤 |
| EP2655362A1 (en) | 2010-12-22 | 2013-10-30 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| CN103619846B (zh) | 2011-06-27 | 2016-08-17 | 詹森药业有限公司 | 1-芳基-4-甲基-[1,2,4]三唑[4,3-a]喹喔啉衍生物 |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| US9303020B2 (en) | 2012-02-08 | 2016-04-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| CA2862755A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| WO2013148620A1 (en) | 2012-03-27 | 2013-10-03 | Bristol-Myers Squibb Company | Benzofuran derivatives for the treatment of hepatitis c |
| WO2013152391A1 (en) | 2012-04-11 | 2013-10-17 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| WO2013163466A1 (en) * | 2012-04-25 | 2013-10-31 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
| CN102690264B (zh) * | 2012-06-20 | 2014-07-02 | 泰山医学院 | 2-苯基-3-取代咪唑并[1,2-a]吡啶类衍生物及其制备方法 |
| EP2863909B1 (en) | 2012-06-26 | 2020-11-04 | Janssen Pharmaceutica N.V. | Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| ES2607184T3 (es) | 2012-07-09 | 2017-03-29 | Janssen Pharmaceutica, N.V. | Inhibidores de la enzima fosfodiesterasa 10 |
| US8796305B2 (en) | 2012-11-05 | 2014-08-05 | Bayer Pharma Aktiengesellschaft | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
| US9624214B2 (en) * | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US9126998B2 (en) | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| PT2925757T (pt) | 2012-11-19 | 2018-01-09 | Novartis Ag | Compostos e composições para o tratamento de doenças parasitárias |
| US8871754B2 (en) | 2012-11-19 | 2014-10-28 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| US8962651B2 (en) * | 2013-03-13 | 2015-02-24 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| ES2625744T3 (es) | 2013-06-04 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Imidazo[1,2-a]piridinas sustituidas con 3-arilo y su uso |
| TW201609651A (zh) * | 2013-11-12 | 2016-03-16 | 陶氏農業科學公司 | 用於氟化化合物之過程（一） |
| CN106459090A (zh) | 2014-02-19 | 2017-02-22 | 拜耳制药股份公司 | 3‑(嘧啶‑2‑基)咪唑并[1,2‑a]吡啶 |
| PE20161224A1 (es) * | 2014-03-21 | 2016-11-12 | Bristol Myers Squibb Co | Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c |
| CN106715426A (zh) | 2014-03-21 | 2017-05-24 | 拜耳医药股份有限公司 | 氰基取代的咪唑并[1,2‑a]吡啶甲酰胺及其用途 |
| US9920036B2 (en) * | 2014-03-21 | 2018-03-20 | Bristol-Myers Squibb Company | Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis C |
| EP3137463A1 (de) | 2014-05-02 | 2017-03-08 | Bayer Pharma Aktiengesellschaft | Enantiomere des n-(2-amino-5-fluor-2-methylpentyl)-8-[(2,6-difluorbenzyl)oxy]-2-methylimidazo[1,2-a]pyridin-3-carboxamids sowie der di- and tri-fluor-derivate zur behandlung von kardiovaskulären erkrankungen |
| US9957278B2 (en) * | 2014-08-05 | 2018-05-01 | Bristol-Myers Squibb Company | Furopyridine compounds for the treatment of hepatitis C |
| US10100027B2 (en) | 2014-09-26 | 2018-10-16 | Changzhou Yinsheng Pharmaceutical Co., Ltd. | Benzofuran analogue as NS4B inhibitor |
| US10292970B2 (en) | 2014-12-02 | 2019-05-21 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use |
| KR20180053386A (ko) | 2015-09-17 | 2018-05-21 | 마빈 제이. 밀러 | 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물 |
| WO2018184976A1 (de) | 2017-04-05 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
| RU2019123849A (ru) * | 2019-07-29 | 2021-02-01 | Дзе Брихэм Энд Уимен`З Хоспитал, Инк. | Ингибиторы фактора ингибирования миграции макрофагов |
| WO2024102699A1 (en) * | 2022-11-07 | 2024-05-16 | ELANCO US, Inc. | Guanylate cyclase (gc) stimulator formulations and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3502707A (en) * | 1967-09-11 | 1970-03-24 | Mcneilab Inc | Beta-(cyclohexyl and substituted phenyl)-alpha-(4,5-dimethoxy-2-nitro- or aminophenyl) acrylonitriles |
| JPS57123181A (en) | 1981-01-23 | 1982-07-31 | Mitsubishi Paper Mills Ltd | Preparation of pyrazolo (1,5-a) pyridine derivative |
| EP0595150B1 (de) | 1992-10-29 | 1996-07-31 | Hoechst Aktiengesellschaft | Verfahren zur Herstellung von aromatischen Brommethyl-Verbindungen |
| ES2198033T3 (es) * | 1997-12-19 | 2004-01-16 | Eli Lilly And Company | Compuestos de imidazolina hipoglucemicos. |
| PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| AUPQ969800A0 (en) * | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| JP2004525150A (ja) * | 2001-03-30 | 2004-08-19 | スミスクライン ビーチャム コーポレーション | 治療用化合物としてのピラゾロピリジン類の使用 |
| JP2005530788A (ja) * | 2002-05-13 | 2005-10-13 | メルク エンド カムパニー インコーポレーテッド | フェニル置換イミダゾピリジン類およびフェニル置換ベンズイミダゾール類 |
| WO2004041201A2 (en) * | 2002-11-01 | 2004-05-21 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| TW200528459A (en) * | 2004-01-06 | 2005-09-01 | Achillion Pharmaceuticals Inc | Azabenzofuran substituted thioureas; inhibitors of viral replication |
| US7868037B2 (en) * | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US20090281120A1 (en) | 2005-12-12 | 2009-11-12 | Ono Pharmaceutical Co., Ltd | Bicyclic heterocyclic compound |
| US20100298314A1 (en) * | 2006-12-20 | 2010-11-25 | Schering Corporation | Novel jnk inhibitors |
| JP2010518125A (ja) * | 2007-02-12 | 2010-05-27 | インターミューン・インコーポレーテッド | Ｃ型肝炎ウイルス複製の新規な阻害剤 |
| JP2008247878A (ja) | 2007-03-30 | 2008-10-16 | Maruishi Pharmaceutical Co Ltd | イミダゾピリジンおよびイミダゾピリミジン化合物ならびにそれを含有する麻酔または鎮静薬組成物 |
| GB0707000D0 (en) | 2007-04-12 | 2007-05-30 | Istituto Di Ricerche D Biolog | Antiviral agents |
| EP2245023B1 (en) | 2008-02-14 | 2011-12-28 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| WO2009137493A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 2-substituted benzofuran compounds to treat infection with hepatitis c virus |
| WO2009137500A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 6-substituted benzofuran compounds to treat infection with hepatitis c virus |
| US8048887B2 (en) * | 2008-09-11 | 2011-11-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7994171B2 (en) * | 2008-09-11 | 2011-08-09 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
-
2009
- 2009-08-28 US US12/549,983 patent/US8198449B2/en active Active
- 2009-09-02 MX MX2011002471A patent/MX2011002471A/es active IP Right Grant
- 2009-09-02 CN CN201410060239.8A patent/CN103864783A/zh active Pending
- 2009-09-02 AU AU2009291993A patent/AU2009291993A1/en not_active Abandoned
- 2009-09-02 JP JP2011526911A patent/JP2012502099A/ja active Pending
- 2009-09-02 WO PCT/US2009/055648 patent/WO2010030538A2/en not_active Ceased
- 2009-09-02 EP EP09792143.1A patent/EP2331502B1/en not_active Not-in-force
- 2009-09-02 CN CN200980144810.1A patent/CN102209711B/zh not_active Expired - Fee Related
- 2009-09-02 KR KR1020117008086A patent/KR20110056537A/ko not_active Withdrawn
- 2009-09-11 TW TW098130826A patent/TW201014855A/zh unknown
- 2009-09-11 AR ARP090103513A patent/AR073586A1/es not_active Application Discontinuation
-
2012
- 2012-05-14 US US13/470,727 patent/US8536338B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502099A5 (enExample) | ||
| JP6018715B2 (ja) | 抗ウイルス化合物 | |
| JP2012501312A5 (enExample) | ||
| JP2012528166A5 (enExample) | ||
| JP5808496B2 (ja) | 抗ウイルス化合物 | |
| JP6039067B2 (ja) | 抗ウイルス剤としてのトリアゾール化合物 | |
| JP5923181B2 (ja) | Ｈｃｖｎｓ５ａの阻害剤 | |
| JP2011520906A5 (enExample) | ||
| JP2010510233A5 (enExample) | ||
| JP2013522224A5 (enExample) | ||
| ES2967119T3 (es) | Compuestos inhibidores de metaloenzimas | |
| JP2006504658A5 (enExample) | ||
| JP2012525431A5 (enExample) | ||
| JP6092261B2 (ja) | 抗ウイルス化合物 | |
| US10426762B2 (en) | Inhibitors of hepatitis C virus polymerase | |
| JP2013520507A5 (enExample) | ||
| CN105051033B (zh) | 抗病毒化合物 | |
| JP2016510050A (ja) | 抗ウイルス性化合物 | |
| CN105026386A (zh) | 抗病毒化合物 | |
| HK1217200B (en) | Antiviral compounds |